Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCPK - Delayed Quote USD

ZYUS Life Sciences Corporation (ZLSCF)

Compare
0.6000
0.0000
(0.00%)
At close: April 4 at 4:00:00 PM EDT
Loading Chart for ZLSCF
  • Previous Close 0.0000
  • Open 0.6000
  • Bid 0.5000 x --
  • Ask 0.5800 x --
  • Day's Range 0.6000 - 0.6000
  • 52 Week Range 0.0005 - 0.8000
  • Volume 1,204
  • Avg. Volume 249
  • Market Cap (intraday) 44.615M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada and internationally. The company offers cannabinoid oils, softgel capsules, and topical creams. ZYUS Life Sciences Corporation was founded in 2018 and is based in Saskatoon, Canada.

www.zyus.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ZLSCF

View More

Performance Overview: ZLSCF

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

ZLSCF
119,900.00%
S&P/TSX Composite index (^GSPTSE)
5.80%

1-Year Return

ZLSCF
23.53%
S&P/TSX Composite index (^GSPTSE)
5.18%

3-Year Return

ZLSCF
23.08%
S&P/TSX Composite index (^GSPTSE)
5.02%

5-Year Return

ZLSCF
23.08%
S&P/TSX Composite index (^GSPTSE)
79.26%

Compare To: ZLSCF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZLSCF

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    40.79M

  • Enterprise Value

    46.13M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    133.97

  • Price/Book (mrq)

    4.26

  • Enterprise Value/Revenue

    145.12

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.33%

  • Return on Equity (ttm)

    -118.64%

  • Revenue (ttm)

    452k

  • Net Income Avi to Common (ttm)

    -36.55M

  • Diluted EPS (ttm)

    -0.4100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    346k

  • Total Debt/Equity (mrq)

    53.34%

  • Levered Free Cash Flow (ttm)

    -2.63M

Research Analysis: ZLSCF

View More

Company Insights: ZLSCF

Research Reports: ZLSCF

View More

People Also Watch